viewAdvanced Oncotherapy PLC
Advanced Oncotherapy set to benefit from Large Hadron Collider spin-off
Dr Michael Sinclair, CEO of Advanced Oncotherapy (LON:AVO), tells Proactive Investors his firm is uniquely placed to exploit a strand of particle physics from the Cern Laboratories to combat cancer tumours. Mike says that AVO is working towards producing proton beam therapy machines, at a fraction of the cost of existing machines, using its own patented technology.
Quick facts: Advanced Oncotherapy PLC
Price: 25.2 GBX
LSE:AVO
Market: LSE
Market Cap: £77.21 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Advanced Oncotherapy PLC named herein, including the promotion by the Company of Advanced Oncotherapy PLC in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
Advanced Oncotherapy focuses on regulatory approval for LIGHT cancer...
Most read
Mining
The gold sector catches fire around the world, as US$2,000 breached, share...
1 day, 4 hours ago
Tech
Coronavirus: UK rolls out ‘game changer’ tests; govt mulls more bans; cruise...
3 days, 10 hours ago
